Nuvo Research® to Receive US$2.0 Million

                   Nuvo Research® to Receive US$2.0 Million

PR Newswire

MISSISSAUGA, ON, Oct. 10, 2013

Milestone Payment Related to Pliaglis Brazil Approval and Launch

MISSISSAUGA, ON, Oct. 10, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a
specialty pharmaceutical company dedicated to building a portfolio of products
for the topical treatment of pain and the development of its immune modulating
drug candidate WF10 today announced that the Company has been advised by its
worldwide Pliaglis licensing partner, Galderma S.A. (Galderma), that Pliaglis
has been approved for sale and marketing in Brazil and that it expects to
launch Pliaglis in Brazil in early 2014. This entitles Nuvo to a US$2.0
million milestone payment that it expects to receive from Galderma in early

"We are pleased  that Pliaglis  has been approved  for sale  and marketing  in 
Brazil which is one of the  largest potential markets for Pliaglis," said  Dr. 
Bradley Galer, President of Nuvo's Pain Group. "Pliaglis is now approved  for 
sale and marketing in 16 European countries, the United States, Argentina  and 
Brazil with additional approvals expected over the next two years."

Important Safety Information

Indication: PLIAGLIS® (lidocaine and tetracaine) Cream 7% / 7% is indicated in
adults  to  produce  local  dermal   anaesthesia  on  intact  skin  prior   to 
dermatological   procedures.    Contraindications:   PLIAGLIS®    Cream    is 
contraindicated in patients with a  known history of sensitivity to  lidocaine 
or tetracaine, or local  anesthetics of the  amide or ester  type and is  also 
contraindicated in patients  with sensitivity to  para-aminobenzoic (PABA)  or 
any components of the product. Pliaglis should not be used on mucous membranes
or on broken or irritated skin. Adverse Events: In clinical studies, the most
common local  reactions were  erythema (47%),  skin discoloration  (16%),  and 
edema (14%). The most common systemic adverse events were headache, vomiting,
dizziness, and  fever,  all  of  which occurred  with  a  frequency  of  <1%. 
Warnings/Precautions: Methemoglobinemia has been associated with use of  local 
anesthetics such as tetracaine. PLIAGLIS®  Cream should be used with  caution 
in patients  with  severe  hepatic  disease. When  using  PLIAGLIS®  Cream  in 
conjunction with other local anesthetic  agents, the total dose of  anesthetic 
should be  considered  due  to  the  potential  for  additive  systemic  toxic 
effects. Contact with the  eyes should be avoided.  The treated area  should 
not be occluded before removing Pliaglis from the skin.

You are encouraged to  report negative side effects  of prescription drugs  to 
the FDA. Visit or call 1-800-FDA-1088.

About Nuvo Research Inc.

Nuvo (TSX:NRI)  is a  specialty pharmaceutical  company focused  on  improving 
patient's lives  by developing  and commercializing  innovative products  that 
address unmet medical needs. The Company has a diverse portfolio of  products 
in the areas of topical pain and immunology.

Nuvo's marketed products include Pennsaid^® (a topical treatment for the signs
and symptoms  of  osteoarthritis  of  the knee),  Pliaglis  (a  topical  local 
anesthetic) and  the  heated  lidocaine/tetracaine  patch  (HLT  Patch).  For 
additional Company information visit

About Galderma

Galderma  is  a  global  company  founded  in  1981  committed  to  delivering 
innovative medical  solutions  to  meet the  dermatological  needs  of  people 
throughout their lifetime  while serving healthcare  professionals around  the 
world. The company has 33 wholly-owned affiliates with a worldwide network  of 
distributors and  more  than  4,500 employees.  Galderma's  extensive  product 
portfolio is available in  80 countries and treats  a range of  dermatological 
conditions   including:    acne,   rosacea,    onychomycosis,   psoriasis    & 
steroid-responsive dermatoses, pigmentary disorders,  skin cancer and  medical 
solutions for skin senescence.

With approximately 19% of revenues invested each year to discover and  develop 
new products and  access innovative technologies,  the company is  one of  the 
world's leading  investors  in  dermatology  R&D.  Five  state-of-the-art  R&D 
centers and four manufacturing sites are  dedicated to providing a wide  range 
of innovative medical solutions which meet the highest standards of safety and

Strategic brands includeEpiduo^®, Oracea^®, Clobex^®, Differin^®,
Rozex^®/MetroGel^®, Silkis^®/Vectical^®, Tri-Luma^®, Loceryl^®, Cetaphil^®,
Metvix^®, Azzalure^®, Restylane^®and Emervel^®.

Forward-Looking Statements

Certain statements in this news release constitute forward-looking  statements 
within the meaning of applicable securities laws. Forward-looking  statements 
include, but are not  limited to, statements  concerning the Company's  future 
objectives, strategies to achieve those objectives, as well as statements with
respect to management's beliefs, plans, estimates, and intentions, and similar
statements  concerning  anticipated  future  events,  results,  circumstances, 
performance or expectations  that are not  historical facts.  Forward-looking 
statements  generally  can  be  identified  by  the  use  of   forward-looking 
terminology such as "outlook", "objective", "may", "will", "expect", "intend",
"estimate", "anticipate",  "believe",  "should",  "plans"  or  "continue",  or 
similar   expressions   suggesting   future   outcomes   or   events.    Such 
forward-looking statements reflect management's current beliefs and are  based 
on information currently available to management. Forward-looking  statements 
involve risks  and uncertainties  that could  cause actual  results to  differ 
materially from those  contemplated by  such statements.  Factors that  could 
cause such differences include the need for additional financing, the  current 
economic  environment,  dependence  on   sales  and  marketing   partnerships, 
competitive developments,  as  well as  other  risk factors  included  in  the 
Company's annual  information form  dated  March 27,  2013 under  the  heading 
"Risks Factors"  and  as  described from  time  to  time in  the  reports  and 
disclosure documents filed by the Company with Canadian securities  regulatory 
agencies and commissions. This list is not exhaustive of the factors that may
impact the  Company's forward-looking  statements.  These and  other  factors 
should be considered carefully and readers should not place undue reliance  on 
the Company's forward-looking statements.  As a result  of the foregoing  and 
other factors, no assurance can be given as to any such future results, levels
of activity  or achievements  and neither  the Company  nor any  other  person 
assumes  responsibility   for  the   accuracy   and  completeness   of   these 
forward-looking statements. The factors  underlying current expectations  are 
dynamic and  subject  to  change. Although  the  forward-looking  information 
contained in this  news release  is based  upon what  management believes  are 
reasonable assumptions, there can be no assurance that actual results will  be 
consistent with these forward-looking statements. Certain statements included
in this news  release may be  considered "financial outlook"  for purposes  of 
applicable securities laws, and such financial outlook may not be  appropriate 
for purposes other than this news release. All forward-looking statements  in 
this  news  release  are  qualified  by  these  cautionary  statements.   The 
forward-looking statements contained herein  are made as of  the date of  this 
news release and except as required by applicable law, the Company  undertakes 
no obligation  to publicly  update or  revise any  forward-looking  statement, 
whether as a result of new information, future events or otherwise.

SOURCE Nuvo Research Inc.


Karin Falck
Public and Media Relations Officer
+41 (0) 797226075

Nuvo Research Inc.
Press spacebar to pause and continue. Press esc to stop.